Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cellectar Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FLORHAM PARK, N.J., JULY 30, 2026 (GLOBE NEWSWIRE) -- CELLECTAR BIOSCIENCES, INC. (NASDAQ: CLRB), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF DRUGS FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDE A CORPORATE UPDATE ON AUGUST 13, 2026, AT 8:30 A.M.

CELLECTAR BIOSCIENCES TO REPORT SECOND QUARTER FINANCIAL RESULTS AND HOST A CONFERENCE CALL ON THURSDAY, AUGUST 13, 2026

DEMONSTRATED FAVORABLE SAFETY PROFILE AND PRELIMINARY CLINICAL ACTIVITY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

CELLECTAR BIOSCIENCES ANNOUNCES PUBLICATION OF PHASE 1 STUDY OF IOPOFOSINE I 131 IN PEER-REVIEWED JOURNAL CANCERS

APPROXIMATELY 80% MAJOR RESPONSE RATE AND DURATION OF RESPONSE EXCEEDING 16 MONTHS IN SUBSET ANALYSIS OF PATIENTS TREATED WITH IOPOFOSINE I 131 IMMEDIATELY POST-BTKI THERAPY

CELLECTAR BIOSCIENCES TO HIGHLIGHT COMPELLING NEW EFFICACY DATA FROM PHASE 2B CLOVER WAM STUDY OF IOPOFOSINE I 131 IN R/R WALDENSTRM MACROGLOBULINEMIA AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

ANNOUNCED POSITIVE 12-MONTH FOLLOW-ON DATA FOR IOPOFOSINE I 131 IN RELAPSED/REFRACTORY WALDENSTRM MACROGLOBULINEMIA (R/R WM)

CELLECTAR BIOSCIENCES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

FLORHAM PARK, N.J., MAY 11, 2026 (GLOBE NEWSWIRE) -- CELLECTAR BIOSCIENCES, INC. (NASDAQ: CLRB), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF DRUGS FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDE A CORPORATE UPDATE ON MAY 14, 2026, AT 8:30 A.M. EASTERN TIME.

CELLECTAR BIOSCIENCES TO REPORT FIRST QUARTER FINANCIAL RESULTS AND HOST A CONFERENCE CALL ON THURSDAY, MAY 14, 2026

83.6% ORR AND 61.8% MRR ACHIEVED IN HEAVILY PRETREATED POPULATION WITH MEDIAN DURATION OF RESPONSE OF 17.8 MONTHS FDA-REQUESTED DATASET WITH 12-MONTH FOLLOW-UP ON ALL PATIENTS STRENGTHENS REGULATORY POSITIONING FOR ACCELERATED APPROVAL AND SUPPORTS INITIATION OF CONFIRMATORY TRIAL IN 4Q26 COMPELLING EFFICACY OBSERVED IN POST-BTKI PATIENTS, INCLUDING ~64% MRR AND DURABLE RESPONSES EXCEEDING 18 MONTHS RECENTLY ANNOUNCED OVERSUBSCRIBED FINANCING OF UP TO $140 MILLION WITH LEADING HEALTHCARE INSTITUTIONAL INVESTORS SUPPORTS CONFIRMATORY STUDY AND NDA FILING FOR ACCELERATED APPROVAL OF IOPOFOSINE I 131 IN WALDENSTRM MACROGLOBULINEMIA WITH THE FDA FLORHAM PARK, N.J., MAY 05, 2026 (GLOBE NEWSWIRE) -- CELLECTAR BIOSCIENCES, INC. (NASDAQ: CLRB), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED ONCOLOGY THERAPIES, TODAY ANNOUNCED UPDATED AND MATURE 12-MONTH FOLLOW-UP DATA FROM ITS PHASE 2B CLOVER WAM CLINICAL TRIAL EVALUATING IOPOFOSINE I 131 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) WALDENSTRM MACROGLOBULINEMIA (WM).

CELLECTAR BIOSCIENCES REPORTS POSITIVE 12-MONTH FOLLOW-UP DATA FROM PHASE 2B CLOVER WAM STUDY DEMONSTRATING DURABLE RESPONSES AND EFFICACY OF IOPOFOSINE I 131 IN R/R WALDENSTRM MACROGLOBULINEMIA

OVERSUBSCRIBED FINANCING LED BY NANTAHALA CAPITAL WITH PARTICIPATION FROM BALYASNY ASSET MANAGEMENT, CALIGAN PARTNERS, JANUS HENDERSON INVESTORS, SILVERARC CAPITAL MANAGEMENT, STONEPINE CAPITAL MANAGEMENT, EMPERY ASSET MANAGEMENT LP, STEMPOINT CAPITAL LP AND OTHER DEDICATED HEALTHCARE FUNDS ALONG WITH MEMBERS OF THE EXECUTIVE MANAGEMENT TEAM FINANCING OF UP TO $140 MILLION SUPPORTS CONFIRMATORY STUDY AND NDA FILING FOR ACCELERATED APPROVAL OF IOPOFOSINE I 131 IN WALDENSTRM MACROGLOBULINEMIA WITH THE FDA ANDREW GU OF NANTAHALA CAPITAL MANAGEMENT, LLC TO JOIN THE COMPANY'S BOARD OF DIRECTORS UPON CLOSING FLORHAM PARK, N.J., MAY 05, 2026 (GLOBE NEWSWIRE) -- CELLECTAR BIOSCIENCES, INC. (NASDAQ: CLRB), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED ONCOLOGY THERAPIES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN INSTITUTIONAL INVESTORS, AND AN ADDITIONAL SECURITIES PURCHASE AGREEMENT WITH CERTAIN MEMBERS OF MANAGEMENT, TO ISSUE AND SELL UP TO AN AGGREGATE OF APPROXIMATELY $35 MILLION UPFRONT AND $105 MILLION IN MILESTONE-BASED SECURITIES IN A REGISTERED DIRECT OFFERING OF COMMON STOCK AND A CONCURRENT PRIVATE PLACEMENT OF COMMON STOCK, PRE-FUNDED WARRANTS, AND MILESTONE-BASED WARRANTS.

CELLECTAR BIOSCIENCES ANNOUNCES OVERSUBSCRIBED FINANCING UP TO $140 MILLION

STUDY WILL EVALUATE TUMOR-SPECIFIC UPTAKE, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY SIGNALS OF CLR 125 IN REFRACTORY TNBC, TO DETERMINE RECOMMENDED PHASE 2 DOSE STUDY WILL EVALUATE TUMOR-SPECIFIC UPTAKE, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY SIGNALS OF CLR 125 IN REFRACTORY TNBC, TO DETERMINE RECOMMENDED PHASE 2 DOSE

CELLECTAR ENROLLS FIRST PATIENT IN CLR 125 AUGER-EMITTING RADIOCONJUGATE PHASE 1B CLINICAL TRIAL TARGETING REFRACTORY TRIPLE NEGATIVE BREAST CANCER (TNBC)

ON TRACK TO SUBMIT CONDITIONAL MARKETING AUTHORIZATION FOR IOPOFOSINE I 131 TO EUROPEAN MEDICINES AGENCY IN Q3 2026 FOR POTENTIAL 2027 EU COMMERCIALIZATION AS A TREATMENT FOR WALDENSTRM MACROGLOBULINEMIA

CELLECTAR BIOSCIENCES REPORTS FINANCIAL RESULTS FOR YEAR ENDED 2025 AND PROVIDES CORPORATE UPDATES

FLORHAM PARK, N.J., FEB. 25, 2026 (GLOBE NEWSWIRE) -- CELLECTAR BIOSCIENCES, INC. (NASDAQ: CLRB), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF DRUGS FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDE A CORPORATE UPDATE ON MARCH 4, 2026, AT 8:30 A.M. EASTERN TIME.

Cellectar Biosciences, Inc.

CLRB

Price

Financial Reports

No items found.

Press Releases

Cellectar Biosciences, Inc.

CLRB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CLRB